The Scientific Research Committee (SRC) consists of up to 15 researchers/clinicians in the fields of respiratory and cardiovascular health.
If you would like to read short biographies of our current members, please click on any of the photos below.
NICHS aims to fund high quality local research that demonstrates the greatest impact for the care and prevention of chest, heart and stroke illnesses.
Priorities for funding include research into the prevention, treatment, rehabilitation and care of chest, heart and stroke illnesses. As a consequence of adopting these priorities NICHS is currently funding research involving the study of people and populations, and not animal research.
Applicants must address and demonstrate how their project aligns with our current aims and values outlined in the Research Strategy for 2014-2018 and meet our eligibility and funding criteria.
NICHS is a member of the Association of Medical Research Charities. As such, we ensure the research we fund meets the highest possible standards of quality, accountability, transparency and openness. To ensure high quality research the following processes are in place:
All AMRC members support the AMRC position statement on the use of animals in research. Please visit the AMRC website for the full statement.
Northern Ireland Chest Heart and Stroke (NICHS) is pleased to announce that it will be running a second Research Grant Application and Research Design Workshop with Professor Mike Clarke from QUB at the beginning of 2018 to be held at 21 Dublin Road, Belfast BT2 7HB. The workshop will be conducted in line with the new NICHS Research Strategy review for 2018-2022, being developed on Thursday 11th January 2018.
Throughout the year, the SRC Chair is asked to examine or delegate progress reports from researchers. This is to ensure that research is on track and that it is satisfactory for the charity to meet the agreed costs.
We are very grateful to those who voluntarily assist in the post implementation evaluation of research projects. Scientific Research Committee members give a very considerable amount of time and expertise to contribute to the objective assessment of research grant applications. Independent peer reviewers also donate their time and expertise to provide objective assessments of proposed projects.
Dr Cathy Craig of Queen’s University Belfast was awarded £59,104 to use low-cost body-tracking technology and interactive computer games to improve movement performance in stroke survivors.
This research will involve members of the public and healthcare professionals to provide an informed understanding of how movement in computer games can be used effectively to improve treatment outcomes for stroke patients.
Professor Frank Kee of Queen’s University Belfast received £50,000 towards the Northern Ireland element of a UK-wide research project that will examine the effectiveness of offering financial vouchers to pregnant smokers as incentives to engage with smoking cessation services and quit during and after pregnancy. The local Public Health Agency and Cancer Research UK are also funding this research.
In Northern Ireland, around 43% of women give up smoking before or during their pregnancy, while 18% of mothers continue to smoke during their pregnancy. This project will inform policymakers on whether financial voucher incentives work for smoking cessation in pregnancy and for primary prevention of cardiovascular disease and cancer.
Baby Hearts Research for additional funding request 2016 Professor Helen Dolk. Amount awarded: £49,687
We are allocating funds for a brief extension to the Baby Hearts Study to ensure that the team reach their original target sample of 1,200 participants, which will greatly increase the value for money and power of research findings. We are looking forward to the final results, which are expected in April 2017.
Professor Donna Fitzsimons from Ulster University aims to develop a supportive intervention for carers of people with advanced heart failure and evaluate its acceptability to carers. These results will undoubtedly help us improve services for patients living with heart failure and their carers in Northern Ireland. The project was awarded £49,595.
EpiRiboSH: Epigenetic Effects of Riboflavin Supplementation in a Randomised Control Trial of Hypertensive patients stratified by MTHFR genotype
Dr Diane Less-Murdock was awarded £60,595 to examine the effects of riboflavin (Vitamin B2) supplementation on individuals who have been shown to have a specific genotype which predisposes them to high blood pressure. The findings of this study will provide important information about the mechanism linking this novel genenutrient interaction with hypertension.
Dr Bettina Schock (above) of QUB was allocated £56,078 to examine how gut bacteria and the immune system develop in infants with chronic lung disease, including cystic fibrosis (CF). The bacterial community of the gut of babies and infants is different from that in adults, but usually stabilises by the age of 12 months.
Using the Theory of Planned Behaviour to determine attitudes and knowledge of e-cigarette use in a sample of Northern Irish young people (11-16yrs) and their parents
Dr Liz Simpson of Ulster University was allocated £116,453 to examine e-cigarette use within NI. This two-stage study employs the theory of Planned Behaviour (theory-driven research) and will provide a better understanding of the personal and social factors influencing e-cigarette use.
Professor Tara Moore from Ulster University aims to develop a simple new test to enable opticians to predict the risk of heart disease. It would involve examining tiny blood vessels at the front of the eye. The project was awarded £51,247.
Dr Bettina Schock of QUB was allocated £68,500 to analyse samples from airway cells in children with and without asthma to test the effectiveness of drugs, potentially leading to new treatments.
The Mediterranean diet has been shown to have beneficial effects in preventing cardiovascular disease. Professor Jayne Woodside of QUB has been allocated £80,018 to evaluate if mutual support among members of established community groups can help people change their diet.
Professor Margaret Cupples of QUB, who is also a practising GP, was allocated £43,866 to explore the development of a tool that could be used in general practice to assess patients’ physical activity and diet to help them achieve healthy lifestyles.
Dr Declan McKenna of Ulster University has been allocated £58,787 to try to develop a simple blood test that would identify which patients with high blood pressure are most at risk from cardiovascular disease (CVD). It would also differentiate between the different types of CVD – such as stroke, heart failure and acute myocardial infarction.
“The effect of increased fruit and vegetables intake on epigenetic and transcriptomic endpoints: a pilot randomised controlled trial.”
Dr Jayne Woodside at Queen’s University of Belfast awarded £64,765 to study the effect of increased fruit and vegetables intake on epigenetic and transcriptomic endpoints: a pilot randomised controlled trial.
Increased fruit and vegetable intake (FV) is thought to lead to reduced risk of heart disease and stroke, yet exactly how eating more FV is beneficial for heart health remains to be established, whilst people in Northern Ireland still do not eat recommended number of portions of FV each day. The proposed project uses samples already collected, where 30 healthy volunteers who were low consumers of FV were asked to eat either 2, 5 or 8 portions of FV every day for 4 weeks. All food was provided for the volunteers, and two meals a day were consumed under supervision by the research team. We will analyse these samples for alterations to genetic information that has been shown to be related to risk of heart disease to see whether increasing FV can produce these changes that might improve heart health. This will add to our knowledge of whether increasing FV is good for cardiovascular health, and how exactly these foods are acting in the body.
“The role of intermedin and related peptides as markers of stroke severity and inhibitors of reperfusion injury during stroke therapy.”
Dr Mark Harbison at Queen’s University of Belfast awarded £26,000 to study the role of intermedin and related peptides as markers of stroke severity and inhibitors of reperfusion injury during stroke therapy.
Stroke is caused by blockage of blood vessels in the brain, usually by blood clots, with resulting damage to brain cells (‘infarction’). ‘Clot busting’ drugs reduce stroke morbidity by dissolving the clot and restoring blood flow. Despite the benefits of restoring blood flow, blood returning to the damaged area (reperfusion) may itself cause further brain cell injury by mechanisms such as oxidative damage. Our group has shown in a model simulating infarction and reperfusion in human heart cells (where the situation is almost identical to that in stroke) that a novel protein intermedin is released by cells locally and protects them from damage. In stroke, therefore, intermedin or closely–related proteins produced during infarction and reperfusion may similarly protect the brain from injury. This study will determine whether these proteins are elevated in the blood of patients following stroke, validating that it is involved in the response to stroke. In parallel laboratory studies in human brain and vascular cells, the source of these proteins will be determined and potential benefits of administering them to protect such cells from simulated clotting and reperfusion injury examined. A successful outcome would justify a clinical trial of co–administering such proteins with ‘clot busting’ drugs in stroke patients, to potentially ameliorate the negative consequences of reperfusion injury.
“The effect of vitamin D3 supplementation on insulin resistance and cardiovascular risk factors in people at high risk of cardiovascular disease and type 2 diabetes.”
Dr Michelle McKinley at Queen’s University of Belfast awarded £79,811 to study the effect of vitamin D3 supplementation on insulin resistance and cardiovascular risk factors in people at high risk of cardiovascular disease and type 2 diabetes.
Heart disease and type 2 diabetes are closely related and are two of the leading causes of ill–health and death in the UK, and their prevalence is increasing. Insulin resistance is a condition that predicts the development of type 2 diabetes and heart disease. If simple dietary interventions were effective in reducing insulin resistance this could lead to an improvement in the management of patients at high–risk of heart disease and diabetes. Some intervention studies have shown that vitamin D supplementation might improve insulin resistance but scientific experts have indicated that more studies are needed. The overall aim of this study is to investigate if taking a vitamin D supplement for 6 months can improve insulin resistance in people who are at high risk of heart disease and diabetes. This has clear economic and social implications given the current, and projected, burden of both diabetes and heart disease.People who have low levels of vitamin D in their blood and are at high risk of heart disease will be recruited. They will be assigned by chance to either take a placebo tablet or a vitamin D supplement every day for 6 months. The placebo and vitamin D tablets will look exactly the same so the researchers and people taking part will not know which they are taking. Insulin resistance, vitamin D levels in the blood, blood vessel function, blood pressure and levels of inflammation in the body will be measured at the start and end of the study. Volunteers will come to the Regional Centre for Endocrinology and Diabetes at the Royal Victoria Hospital in Belfast for these assessments. The research team has extensive experience in conducting these low risk assessments and will be in regular contact with participants should they have any questions or concerns. Participants’ travel expenses will be reimbursed and they will also receive a payment on completion of the study as they will be required to give up a few days of their time to come to the RVH in Belfast for assessments.This study would provide robust evidence on whether this straightforward and low–cost health care intervention could be recommended for people at high risk of heart disease and diabetes. The study outcome can be communicated to high risk groups as soon as the research is completed, therefore this research could be of benefit to such people in the short term.
“The Northern Ireland Baby Hearts Study: A case–control study of risk and protective factors for congenital heart disease.”
Professor Helen Dolk at University of Ulster awarded £172,130 for the Northern Ireland Baby Hearts Study: A case–control study of risk and protective factors for congenital heart disease.
Each year in Northern Ireland over 200 babies are born with congenital heart disease (CHD), of which approximately 50 will require paediatric cardiac surgery in the first year of life for severe lesions and more will require interventional cardiac catheterisation and other treatments. Improvements in health care mean that the vast majority of affected children will reach adulthood, CHD contributing significantly to heart disease in the adult population. Primary prevention of CHD, where babies are born with healthy hearts, is possible if the risk factors for CHD are known, and preventive strategies implemented. The overall aim of this project is to contribute to the primary prevention of CHD in Northern Ireland. The objectives are to investigate whether periconceptional folic acid prevents CHD; to investigate risk factors for CHD, including medication use and smoking in pregnancy; describe the prevalence at birth of CHD in Northern Ireland including socioeconomic and geographic distribution, clinical spectrum and survival; estimate the proportion of preventable CHD with specific risk factors. These objectives will be met by a case–control study, and by a birth prevalence study based on the paediatric cardiology database. The case–control study will recruit 400 mothers of babies with CHD, and 800 mothers of unaffected babies.
“A study of therapy against respiratory syncytial virus (RSV).”
Dr Ultan Powers at Queen’s University of Belfast awarded £18,974 to study therapy against respiratory syncytial virus (RSV).
Respiratory syncytial virus (RSV) primarily attacks cells lining the airways in the nose and lungs. Intense inflammation follows with excessive mucus production causing airways obstruction and ‘acute bronchiolitis’. RSV bronchiolitis occurs in winter epidemics and causes illness and occasionally death to infants, especial those with heart or lung diseases. In fact, RSV is the most important cause of bronchiolitis in young infants worldwide. It also causes pneumonia and death in the elderly. There are no adequate treatments or vaccines against RSV. Preventative antibody therapy is expensive and limited to high risk infants. Most infants hospitalized with RSV are not in these high risk groups. To better understand how RSV causes disease in humans, we developed the means in the laboratory to recreate airway cell cultures that look and behave like they would in the nose and lungs. Using these cultures, we were able to recreate the kinds of damage that RSV does in the nose and lungs when it infects young infants. Essentially, this is as close as we can get to infecting authentic cells lining the airways of young infants without actually infecting the infants. These cultures, therefore, provide a unique opportunity to find out how RSV causes disease in young infants. When airway cells are attacked by RSV, they respond by producing substances, such as interferons, that help fight the infection. Interferons, of which there are 3 types (I, II and III), are powerful molecules capable of inhibiting virus propagation. Indeed, type I interferons are successful drugs against hepatitis B and C viruses. Our previous work demonstrated that type III interferons appear to be the most important in responding the RSV infection. In this study we want to determine whether type III interferons have potential as drugs to either prevent or treat RSV infections. We will use our laboratory model of paediatric airway cells, which closely resemble those in the lungs, to address these important questions. If successful, this project may provide the basis for new drugs that help prevent RSV spread or treat people who are suffering from lung infections caused by RSV.
“The impact of telomeres on cardiovascular risk in renal transplant recipients.”
Dr Amy–Jayne McKnight at Queen’s University of Belfast, awarded £26,500 to study the impact of telomeres on cardiovascular risk in renal transplant recipients.
Cardiovascular disease is a major public health issue in the UK and remains the commonest cause of death (from sudden cardiac arrest; heart failure; and stroke). Cardiovascular disease is also the most common cause of death in persons with chronic kidney failure and especially in those treated with dialysis. In Northern Ireland, cardiovascular disease is still responsible for almost half of deaths in people who receive a successful kidney transplant.
Telomeres are specialised structures that help to protect DNA in every living cell in the body. Telomeres act to prevent DNA unraveling (in some ways telomeres are like the ends of shoelaces that prevent the lace from fraying). Telomeres are vital to health and are so important that the 2009 Nobel Prize was awarded for the discovery of how they protect our DNA (genetic) material throughout life. Telomere length has been independently associated with cardiovascular disease and kidney disease; however, research last year showed that the biology behind this effect was complicated and urgently needed further research.
We have successfully completed a pilot study that examined two inherited markers that influence telomeres. This work was presented in the USA in 2010 and led to our team developing a cost–effective, efficient approach to comprehensively investigate telomere biology.
This project will use this approach to investigate the impact of telomere biology on cardiovascular disease, kidney disease and the risk of death. Several commercial companies already plan to offer ‘telomere tests’ to assess individual health (e.g. www.telomehealth.com) and drugs are now being marketed to reduce the risks associated with telomere shortening (e.g. www.tasciences.com/ta–65/testimonials). Altered telomere biology may have an impact on a patient’s long term health or on an individual’s response to treatment. We plan to identify key factors that influence how telomeres work in health and disease.
This work could lead to new screening tests for cardiovascular disease or even be developed as tests that will predict response to drugs. Finding out which telomere patterns are linked to higher risks of cardiovascular disease may allow more accurate prediction of those individuals most at risk, or help to identify persons who would benefit from earlier treatment to prevent cardiovascular and kidney disease.
“The physical activity intervention versus pulmonary rehabilitation in COPD.”
Dr Brenda O’Neill at University of Ulste, awarded £79,643 to study the physical activity intervention versus pulmonary rehabilitation in COPD.
Patients with COPD who completed recent studies with our team told us that they are interested in including exercise and physical activity to help improve their health. Pulmonary rehabilitation is an exercise programme which is effective. However, it does not suit everyone with COPD, and is not widely available throughout all of Northern Ireland. Other options for increasing exercise and physical activity do not seem to be offered.
The purpose of this study is to explore a home–based walking programme to improve the physical activity levels of patients with COPD. We will compare the physical activity levels of patients who receive the home–based walking programme, to those who receive pulmonary rehabilitation. Methods. Half the patients (25 patients) will receive the walking programme, and half (25 patients) will receive the pulmonary rehabilitation programme.
The walking programme includes advice about physical activity, and a small monitor called a pedometer which people can wear. It counts how many steps people can walk each day. During the study patients will try to walk a little further every week. The pulmonary rehabilitation programme will be delivered twice weekly to small groups of patients attending a hospital gym. We will ask patients for their views about the two programmes and we will find out what people liked or disliked about them. We will also measure patients’ physical activity levels and quality of life at the start and end of the study, and after 3 months. Lastly we will calculate how much it costs to deliver the two programmes and we will be able to compare this cost.
We are keen to provide important information on the benefits of these 2 treatments. The physical activity treatment could offer an exciting, cheap and alternative choice to pulmonary rehabilitation. This study will provide us with all the information we need to carry out a large study on physical activity training in COPD.
“The accumulated brisk walking and cardiovascular risk in an ‘at risk’ population: investigation of novel effects on HDL functionality.”
Dr Alison Gallagher at University of Ulster, awarded £57,478 to study the accumulated brisk walking and cardiovascular risk in an ‘at risk’ population: investigation of novel effects on HDL functionality.
It is recognised that people who are overweight or obese are at greatly increased risk of developing heart disease. As a result of less physical exercise and poor diet the levels of obesity are increasing in our population. This will result in higher rates of heart disease and other obesity related problems. It has long been known that physical exercise is an important way of helping to control weight and reduce the risk of heart disease. However, recent evidence suggests that exercise may have benefits for the heart even if it is not associated with weight loss.
Experts recommend that every adult should take at least 30 minutes of moderate intensity physical activity every day. For obese individuals, not used to regular activity, even this modest amount and intensity represents a significant change from their normal daily routine. Accumulating 30 minutes of walking in short bouts spread throughout the day and incorporated into one’s normal daily routine may be a simple effective way of meeting current recommendations. To date this ‘lifestyle’ approach to exercise has been shown to modify traditional CVD risk factors in normal weight individuals, but it has yet to be fully evaluated in overweight/obese individuals.Waking is a popular, familiar, convenient and inexpensive form of exercise that can be easily incorporated into everyday life. Given the rising rates of obesity in our population the successful implementation of a walking programme that reduces heart disease risk would represent a simple, inexpensive and effective intervention, which could be applied widely.
Recent research suggests that changes in functionality of HDL (a blood lipid fraction) may help protect against CVD development. Factors (such as exercise training) which reduce systemic inflammation may also help reduce CVD risk. We recently undertook a 6–month brisk walking intervention in a group of overweight/obese individuals and observed beneficial effects on arterial stiffness (a novel marker of CVD risk) and fitness and these beneficial effects were sustained four months after the end of the intervention. Furthermore we observed these beneficial effects in the absence of any changes in body weight or diet of the participants over the study period.The proposed project will analyze stored blood samples from this study to determine whether exercise training in ‘at risk’ individuals results in favourable shifts in the function of the so–called good cholesterol (HDL) fraction. These novel results will provide valuable insights on the impact of exercise on lipid sub–fractions in a CVD ‘at risk’ group.
“The role of Suppressor of Cytokine Signaling (SOCS1) in refractory asthma.”
Professor Liam Heaney at Queen’s University of Belfast, awarded £109,080 to study the role of Suppressor of Cytokine Signaling (SOCS1) in refractory asthma.
In the UK, 5.1 million people suffer from asthma, which is a condition that affects the airways causing breathlessness, cough and wheeze. Most asthmatics respond well to currently available inhaled medication but 10% have “difficult asthma”, with poor control and frequent hospital admissions accounting for 60% of total NHS asthma spend, equating to ca £700 millions per annum. These patients with severe disease do not respond to treatment with standard doses of inhaled ‘steroid’ therapy and they require systemic steroid tablets to maintain some degree of disease control.
The problem with steroid tablets is that they cause very severe side–effects including obesity, diabetes, high blood pressure, brittle bones and depression amongst many others. If we could understand the reason why these patients do not respond to steroids, we could potentially treat this and thus make them more responsive to normal steroid doses in asthma.
In the last year, we have studied small tissue samples taken from the airways of patients with severe asthma, who require steroid tablets to maintain disease control. We have examined the expression of thousands of genes in these samples using modern techniques which allow us to look at the entire human gene set. From this unique information, we have identified that a very important ‘molecular switch’ called SOCS1 is reduced in the lining cells of the lungs of patients with severe asthma.
This project will try and understand why there is this failure to turn on this important switch. It will also examine, in the laboratory, a potential strategy to ‘switch on’ SOCS1 in the airway, using a naturally occurring compound called interferon gamma to try and increase or improve the response to steroid treatment.